Header Logo

Connection

Wendy Stevens to Viral Load

Back to Details
This is a "connection" page, showing publications Wendy Stevens has written about Viral Load.
Wendy Stevens
Connection Strength
5,901
Viral Load
  1. Options to Expand HIV Viral Load Testing in South Africa: Evaluation of the GeneXpert® HIV-1 Viral Load Assay. PLoS One. 2016; 11(12):e0168244.
    View in: PubMed
    Score: 0,412
  2. Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa. J Clin Microbiol. 2015 May; 53(5):1616-21.
    View in: PubMed
    Score: 0,364
  3. Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Med. 2014 Sep 08; 12:173.
    View in: PubMed
    Score: 0,352
  4. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol. J Virol Methods. 2013 Dec; 194(1-2):300-7.
    View in: PubMed
    Score: 0,328
  5. Use of a prequalification panel for rapid scale-up of high-throughput HIV viral load testing. J Clin Microbiol. 2012 Dec; 50(12):4083-6.
    View in: PubMed
    Score: 0,307
  6. Abbott RealTime HIV-1 m2000rt viral load testing: manual extraction versus the automated m2000sp extraction. J Virol Methods. 2011 Mar; 172(1-2):78-80.
    View in: PubMed
    Score: 0,272
  7. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis. 2010 Apr 15; 201 Suppl 1:S16-26.
    View in: PubMed
    Score: 0,260
  8. Challenges in implementing HIV load testing in South Africa. J Infect Dis. 2010 Apr 15; 201 Suppl 1:S78-84.
    View in: PubMed
    Score: 0,260
  9. Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol. 2009 Oct; 47(10):3400-2.
    View in: PubMed
    Score: 0,248
  10. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol. 2009 Jul; 47(7):2209-17.
    View in: PubMed
    Score: 0,243
  11. Evaluation of the performance of the automated NucliSENS easyMAG and EasyQ systems versus the Roche AmpliPrep-AMPLICOR combination for high-throughput monitoring of human immunodeficiency virus load. J Clin Microbiol. 2007 Apr; 45(4):1244-9.
    View in: PubMed
    Score: 0,208
  12. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol. 2005 Feb; 43(2):857-61.
    View in: PubMed
    Score: 0,181
  13. National Impact of SARS-CoV-2 Infection on HIV Virological Suppression in South Africa. J Acquir Immune Defic Syndr. 2023 12 15; 94(5):381-386.
    View in: PubMed
    Score: 0,167
  14. HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013-2018. MMWR Morb Mortal Wkly Rep. 2021 May 28; 70(21):775-778.
    View in: PubMed
    Score: 0,140
  15. Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings. Clin Infect Dis. 2020 03 03; 70(6):1014-1020.
    View in: PubMed
    Score: 0,129
  16. Monitoring viral load for the last mile: what will it cost? J Int AIDS Soc. 2019 09; 22(9):e25337.
    View in: PubMed
    Score: 0,124
  17. Impact of a borderless sample transport network for scaling up viral load monitoring: results of a geospatial optimization model for Zambia. J Int AIDS Soc. 2018 12; 21(12):e25206.
    View in: PubMed
    Score: 0,118
  18. Progress with Scale-Up of HIV Viral Load Monitoring - Seven Sub-Saharan African Countries, January 2015-June 2016. MMWR Morb Mortal Wkly Rep. 2016 Dec 02; 65(47):1332-1335.
    View in: PubMed
    Score: 0,103
  19. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature. 2015 Dec 03; 528(7580):S68-76.
    View in: PubMed
    Score: 0,096
  20. Scale-up of HIV Viral Load Monitoring--Seven Sub-Saharan African Countries. MMWR Morb Mortal Wkly Rep. 2015 Nov 27; 64(46):1287-90.
    View in: PubMed
    Score: 0,096
  21. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
    View in: PubMed
    Score: 0,091
  22. Time to reduce CD4+ monitoring for the management of antiretroviral therapy in HIV-infected individuals. S Afr Med J. 2014 Jun 20; 104(8):559-60.
    View in: PubMed
    Score: 0,087
  23. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014; 9(3):e86461.
    View in: PubMed
    Score: 0,085
  24. Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One. 2014; 9(2):e85869.
    View in: PubMed
    Score: 0,085
  25. Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots. J Clin Microbiol. 2013 Jun; 51(6):1899-905.
    View in: PubMed
    Score: 0,080
  26. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis. 2012 Jun; 205(11):1739-44.
    View in: PubMed
    Score: 0,074
  27. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011 Sep 01; 58(1):23-31.
    View in: PubMed
    Score: 0,071
  28. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses. 2012 Feb; 28(2):171-5.
    View in: PubMed
    Score: 0,071
  29. Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. J Virol Methods. 2009 Dec; 162(1-2):218-22.
    View in: PubMed
    Score: 0,062
  30. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther. 2009; 14(5):619-29.
    View in: PubMed
    Score: 0,059
  31. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S131-40.
    View in: PubMed
    Score: 0,055
  32. Clinical performance of an in-house real-time RT-PCR assay using a fluorogenic LUX primer for quantitation of human immunodeficiency virus type-1 (HIV-1). J Virol Methods. 2007 Dec; 146(1-2):14-21.
    View in: PubMed
    Score: 0,054
  33. HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006 Oct; 3(10):e417.
    View in: PubMed
    Score: 0,051
  34. Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR. Mol Biotechnol. 2006 Feb; 32(2):101-10.
    View in: PubMed
    Score: 0,049
  35. Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa. J Virol Methods. 2005 Mar; 124(1-2):105-10.
    View in: PubMed
    Score: 0,045
  36. Identifying acute HIV infection--a major new public health challenge. S Afr Med J. 2004 Jul; 94(7):531.
    View in: PubMed
    Score: 0,043
  37. Cohort profile: the South African National Health Laboratory Service (NHLS) National HIV Cohort. BMJ Open. 2022 10 19; 12(10):e066671.
    View in: PubMed
    Score: 0,039
  38. The performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis. PLoS Med. 2022 08; 19(8):e1004076.
    View in: PubMed
    Score: 0,038
  39. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020 08 01; 34(10):1559-1566.
    View in: PubMed
    Score: 0,033
  40. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infect Dis. 2017 01; 17(1):e26-e29.
    View in: PubMed
    Score: 0,026
  41. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
    View in: PubMed
    Score: 0,025
  42. Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infect Dis. 2016 Nov; 16(11):e267-e275.
    View in: PubMed
    Score: 0,025
  43. CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and meta-analysis. J Int AIDS Soc. 2015; 18:20061.
    View in: PubMed
    Score: 0,023
  44. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. Clin Infect Dis. 2015 May 15; 60(10):1552-8.
    View in: PubMed
    Score: 0,023
  45. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One. 2013; 8(12):e74900.
    View in: PubMed
    Score: 0,021
  46. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS. 2012 Aug 24; 26(13):1663-72.
    View in: PubMed
    Score: 0,019
  47. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17; 26(11):1345-54.
    View in: PubMed
    Score: 0,019
  48. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
    View in: PubMed
    Score: 0,019
  49. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis. 2012 Sep; 55(5):737-45.
    View in: PubMed
    Score: 0,019
  50. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,018
  51. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct; 11(10):750-9.
    View in: PubMed
    Score: 0,018
  52. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc. 2011 May 15; 14:24.
    View in: PubMed
    Score: 0,017
  53. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010 Sep 13; 5(9):e12598.
    View in: PubMed
    Score: 0,017
  54. Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women. J Int AIDS Soc. 2010 Sep 07; 13:33.
    View in: PubMed
    Score: 0,017
  55. Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol. 2005 Dec; 43(12):5950-6.
    View in: PubMed
    Score: 0,012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.